Literature DB >> 6742201

Metabolism of pure human erythropoietin in the rat.

D S Emmanouel, E Goldwasser, A I Katz.   

Abstract

The metabolism of pure human erythropoietin (EPO) labeled with 125I was studied in the rat. Concentrations of the labeled hormone (125I-EPO) in plasma and urine were measured by both trichloroacetic acid precipitation and gel filtration. During steady-state conditions the metabolic clearance rate of 125I-EPO was slow, averaging 256 +/- 7 microliter. min-1 X kg-1 of which only 19 +/- 2 microliter X min-1 X kg-1 (or 7.4 +/- 0.8% of the metabolic clearance rate) could be accounted for by excretion of the labeled hormone in the urine. Urinary clearance of 125I-EPO amounted to less than 0.3% of the glomerular filtration rate, and there was no detectable arteriovenous concentration difference of 125I-EPO across the kidney. After both pulse injection and constant infusion to equilibrium, disappearance of 125I-EPO from the circulation could be approximated by a single exponential function: plasma half-life was 3.5 +/- 0.2 h in normal rats and was prolonged to 4.4 +/- 0.3 h (P less than 0.05) in animals with ligated renal pedicles. Although kidney homogenates degraded 125I-EPO in vitro (optimum pH 4.5), the hormone did not accumulate in the kidney when injected intravenously. We conclude that EPO metabolism is extremely sluggish compared with that of other polypeptide hormones. Whereas kidney tissue is capable of degrading EPO in vitro, the physicochemical characteristics of this glycoprotein (molecular size, shape, and charge) probably impede its access to degrading sites and therefore account for the limited contribution of renal extraction and excretion to the metabolic clearance of the hormone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6742201     DOI: 10.1152/ajprenal.1984.247.1.F168

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Direct relationship of antepartum glucose control and fetal erythropoietin in human type 1 (insulin-dependent) diabetic pregnancy.

Authors:  J A Widness; K A Teramo; G K Clemons; P Voutilainen; U H Stenman; S M McKinlay; R Schwartz
Journal:  Diabetologia       Date:  1990-06       Impact factor: 10.122

Review 2.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Renal clearance of endogenous erythropoietin in patients with proteinuria.

Authors:  M Nowicki; F Kokot; M Kokot; A Bar; J Duława
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 4.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Change in erythropoietin pharmacokinetics following hematopoietic transplantation.

Authors:  J A Widness; R L Schmidt; R J Hohl; F D Goldman; N H Al-Huniti; K J Freise; P Veng-Pedersen
Journal:  Clin Pharmacol Ther       Date:  2007-04-11       Impact factor: 6.875

6.  Improvement of in vivo efficacy of recombinant human erythropoietin by encapsulation in PEG-PLA micelle.

Authors:  Yanan Shi; Wan Huang; Rongcai Liang; Kaoxiang Sun; Fangxi Zhang; Wanhui Liu; Youxin Li
Journal:  Int J Nanomedicine       Date:  2012-12-27

7.  Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions.

Authors:  C E Lezón; M P Martínez; M I Conti; C E Bozzini
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.